GET DAILY SIGNALSImmutep (IMMP) ADRs Slide -34% Over 30 Days Amid LAG-3 Pipeline Pressure
Key Takeaways
- Immutep American Depositary Receipts fell roughly 34% over the trailing 30 days, sliding from a split-adjusted close near $4.65 on September 30, 2026, to about $3.06 in late October 2026.
- The pullback extends a much deeper decline, with the stock down approximately 60% over the past quarter as investors reassess the company's LAG-3 immunotherapy franchise.
- Near-term selling has been compounded by GSK's decision to discontinue a Phase 2 study of an Immutep-licensed anti-LAG-3 antibody in ulcerative colitis following an interim analysis.
- Immutep has narrowed eftilagimod alfa development to head and neck squamous cell carcinoma and neoadjuvant soft tissue sarcoma while completing a root-cause analysis of the discontinued lung-cancer trial.
- Sentiment remains pressured by an ongoing securities class action covering the period leading up to the March 2026 TACTI-004 futility announcement.
- For additional data, review Immutep's Price Targets, Earnings, and Forecast pages.
- Explore curated Trending AI Robots trading this and thousands of other tickers.
Immutep (IMMP) Company Overview and Market Position
Immutep Limited is an Australian clinical-stage biotechnology company that pioneers immunotherapies targeting the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. Listed on the ASX and traded on Nasdaq through ADRs under the ticker IMMP, the company develops candidates for both oncology and autoimmune disease. Its lead program, eftilagimod alfa (efti), is a first-in-class soluble LAG-3 protein and MHC Class II agonist designed to activate antigen-presenting cells and trigger a broad anti-cancer immune response. The broader pipeline includes IMP761, an agonist anti-LAG-3 antibody for autoimmune conditions, and IMP701, an antagonist anti-LAG-3 antibody. Investors follow the stock for its position in the competitive LAG-3 space and for data readouts across its clinical programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Immutep (IMMP) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, IMMP declined approximately 34%, moving from a split-adjusted close of about $4.65 on September 30, 2026, to roughly $3.06 in late October 2026. The downward move was persistent rather than a single-day event, with the ADRs steadily grinding lower through October even as the company reported incremental pipeline updates.
The quarterly picture is starker. From a split-adjusted level near $7.60 in late July 2026, the stock has dropped roughly 60% to its current range. This multi-month slide reflects a sustained repricing of the company's lead oncology program following the March 2026 futility halt of the TACTI-004 Phase 3 trial in first-line non-small cell lung cancer, rather than a temporary technical correction.
What Drove IMMP Stock Price in the Last 30 Days
The recent 30-day decline has been driven primarily by continued fallout from the TACTI-004 failure and fresh negative read-throughs for the LAG-3 franchise. In October 2026, GSK announced the discontinuation of a Phase 2 study of an anti-LAG-3 antibody licensed from Immutep in ulcerative colitis after an interim analysis, a development that compounded investor concerns about the broader LAG-3 mechanism despite GSK bearing the program's costs.
Immutep also continued its root-cause analysis of TACTI-004, which identified subtle N-glycan structural differences between efti manufactured at 200-litre and 2,000-litre scales. The company contracted a new 200-litre manufacturing run and refocused registration-directed development on head and neck squamous cell carcinoma and neoadjuvant soft tissue sarcoma. In late October, the company presented health-related quality-of-life data from the investigator-initiated EFTISARC-NEO Phase 2 trial in soft tissue sarcoma, a positive but non-registrational update that did little to offset the prevailing negative sentiment. An ongoing securities class action and a late-September ADR consolidation added further pressure to the trading backdrop.
What Drove IMMP Stock Performance Over the Last Quarter
The quarterly decline is anchored to the March 13, 2026, announcement that an Independent Data Monitoring Committee recommended discontinuing TACTI-004, a Phase 3 trial of efti combined with Merck's Keytruda and chemotherapy in first-line non-small cell lung cancer, following a planned interim futility analysis. The announcement triggered a steep single-session selloff and marked a turning point in the investment narrative, shifting the market's focus from a potential blockbuster indication to questions about the durability of the broader efti program.
Over the following months, the company's pivot away from the lung-cancer setting, the ongoing manufacturing investigation, licensing-partner updates, and the GSK ulcerative colitis discontinuation reinforced a more cautious outlook. While the company has extended its cash runway well beyond its prior guidance of the second quarter of 2027, the market has continued to price in reduced probability of near-term commercial success for the lead asset.
IMMP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the outcome of Immutep's root-cause analysis of TACTI-004 and the company's ability to advance efti in head and neck squamous cell carcinoma and soft tissue sarcoma, where regulatory designations such as Fast Track and Orphan Drug status are in place. Progress on the new 200-litre manufacturing run, updated cash-runway guidance, and any signals from licensing partners including Dr. Reddy's and GSK will also be key. Developments in the securities class action and broader LAG-3 competitive landscape may further influence sentiment. As with all clinical-stage biotechnology companies, upcoming trial data, regulatory feedback, and financing decisions carry material risk and should be evaluated carefully. From what I see, the next few data points could clarify the path forward.
Using Tickeron’s AI Tools in My Research
In my own workflow for tracking clinical-stage names like IMMP, I often turn to Tickeron’s Trending AI Robots to review automated strategies that have performed well on similar volatile biotech tickers. The page surfaces top-performing bots from a broad universe, helping me quickly compare approaches that align with different risk levels and time horizons without having to screen everything manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMMP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IMMP turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IMMP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 59 cases where IMMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 211 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMMP as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for IMMP entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.401) is normal, around the industry mean (3.154). P/E Ratio (-0.287) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-cancer therapeutics
Industry Biotechnology
Advertisement